Prospective Study of Allopurinol Treatment That Improves Endothelial Function by Decreasing Uric Acid Levels of Patients With Chronic Kidney Disease
Overview
- Phase
- Not Applicable
- Intervention
- allopurinol
- Conditions
- Hyperuricemia
- Sponsor
- Istanbul University
- Enrollment
- 20
- Locations
- 1
- Primary Endpoint
- Endothelial function improvement with uric acid lowering treatment
- Status
- Completed
- Last Updated
- 16 years ago
Overview
Brief Summary
In this prospective study, the investigators aimed to evaluate the effects of improved hyperuricemia, a minor cardiovascular risk factor, on endothelial dysfunction in patients with chronic kidney disease.
Detailed Description
Endothelial dysfunction (ED) is a key event in the development of atherosclerotic cardiovascular disease observed in patients with chronic kidney disease (CKD). Experimental models have shown that hyperuricemia causes hypertension and renin angiotensin system activation. In this prospective study, the investigators aimed to evaluate the effects of improved hyperuricemia, a minor cardiovascular risk factor, on ED in patients with CKD.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Laboratory finding of hyperuricemia
- •Patients between ages of 18 and 60 years
- •Non-diabetic patients
- •Creatinine clearance values between 20 and 60 mL/min/1.73 m2
Exclusion Criteria
- •Low (\< 20 ml/min/1.73 m2) creatinine clearance,
- •Patients with diabetes mellitus, ischemic heart disease, acute coronary syndrome, congestive heart failure (CHF) (New York Heart Association class II or greater), valvular heart disease and a history of cerebral infarction or transient ischemic attack.
- •Patients taking urate lowering medication (allopurinol and probenecid)
Arms & Interventions
Allopurinol
Hyperuricemic (uric acid (UA)\>7 mg/dL), nondiabetic CKD patients without any comorbidity, age\<60 years with creatinine clearance (CrCl) between 20 and 60ml/min were evaluated.
Intervention: allopurinol
Outcomes
Primary Outcomes
Endothelial function improvement with uric acid lowering treatment
Time Frame: 1 year